Understanding a genetic marker for prostate cancer that resists treatment
Elucidating a novel molecular biomarker for castration-resistant prostate cancer
This work aims to find a genetic clue that helps doctors choose the best treatment for men with prostate cancer that has become resistant to standard hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project ID | NIH-11143262 on NIH RePORTER |
What this research studies
Prostate cancer is a serious concern for many men, and standard hormone therapy, called androgen deprivation therapy (ADT), is often the first treatment. However, the cancer can sometimes become resistant to this therapy, known as castration-resistant prostate cancer (CRPC). Currently, treatment choices for CRPC are often based on past therapies rather than a patient's unique genetics. This project focuses on a specific genetic variation, HSD3B1(1245C), which appears to make prostate cancer more resistant to hormone treatments. By understanding how this genetic variant works, we hope to develop a way to personalize treatment for each patient based on their specific genetic makeup and tumor biology.
Who could benefit from this research
Good fit: Men with prostate cancer, particularly those whose cancer has progressed to a castration-resistant stage, may benefit from future applications of this research.
Not a fit: Patients without prostate cancer or those whose cancer responds well to initial hormone therapy may not directly benefit from this specific research focus.
Why it matters
Potential benefit: If successful, this work could lead to more personalized and effective treatment plans for men with prostate cancer, especially those whose cancer has become resistant to standard therapies.
How similar studies have performed: Previous work from this research group has already provided clear clinical evidence regarding the HSD3B1(1245C) variant, indicating a strong foundation for this continued effort.
Where this research is happening
Coral Gables, United States
- University of Miami School of Medicine — Coral Gables, United States (Active)
Researchers
- Principal investigator: Sharifi, Nima — University of Miami School of Medicine
- Study coordinator: Sharifi, Nima
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.